Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer
NCT ID: NCT03170284
Last Updated: 2017-05-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2008-06-17
2012-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bevacizumab
Participants with advanced (stage IIIB/IV) NSCLC other than predominantly squamous cell histology receiving Bevacizumab in accordance with the summary product characteristics (SPC) is observed.
Bevacizumab
Bevacizumab is prescribed by physicians as per SPC.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab
Bevacizumab is prescribed by physicians as per SPC.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histology or cytology proven inoperable, locally advanced,metastatic or recurrent (stage IIIB/IV) NSCLC other than predominantly squamous cell histology
* First-line treatment is indicated
* No previous treatment with Bevacizumab
Exclusion Criteria
* Hypersensitivity to the active ingredient or to any of the excipients
* Hypersensitivity to products derived from Chinese hamster ovary (CHO) cells or to other recombinant human or humanized antibodies
* Pregnancy
* Bevacizumab is contraindicated in the presence of untreated central nervous system metastases
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ogyi, Orszagos Gyogyszereszeti Intezet
Budapest, , Hungary
Szent Imre Hospital; Dept. of Oncology
Budapest, , Hungary
Orszagos Koranyi TBC es Pulmonologiai Intezet
Budapest, , Hungary
Orszagos Onkologial Intezet; Onkologiai Osztaly X
Budapest, , Hungary
Semmelweis Egyetem X; Pulmonologiai Klinika
Budapest, , Hungary
Uzsoki Utcai Korhaz; Ii. Belgyogyaszat
Budapest, , Hungary
Debrecen Uni Medical School; Dept of Pulmonary Medicine
Debrecen, , Hungary
Hajdú-Bihar Megyei Önkormányzat Kenézy Gyula Hospital; Infektology Department
Debrecen, , Hungary
Csongrad Megyei Onkormanyzat Mellkasi Betegsegek Szakkorhaza
Deszk, , Hungary
Koch Robert Korhaz
Edelény, , Hungary
Megyei Tudogyogyintezet - Pulmonologia
Farkasgyepű, , Hungary
Hospital of Aladar Petz; Dept of Oncoradiology
Győr, , Hungary
Petz Aladár County Teaching Hospital; 2nd Department of Psychiatry
Győr, , Hungary
Bekes Megyei Tudokorhaz; I. Tudobelosztaly
Gyula, , Hungary
Békés Megyei Pándy Kálmán Kórház; Onkologiai tanszek
Gyula, , Hungary
Kaposi Mor County Hospital; Dept. of Oncology
Kaposvár, , Hungary
Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont
Kecskemét, , Hungary
Matrai Állami Gyógyintézet ; Bronchológia
Mátraháza, , Hungary
Szent Ferenc Kórház; Belgyógyászat
Miskolc, , Hungary
Karolina Korhaz
Mosonmagyaróvár, , Hungary
Josa Andras Korhaz; Dept of Oncoradiology
Nyíregyháza, , Hungary
Szabolcs-Szatmar-Bereg County Josa Andras Hospital; 1St Depatment of Pulmonary Medicine
Nyíregyháza, , Hungary
Pécsi Tudományegyetem Áok; Onkoterapias Intezet
Pécs, , Hungary
Baranya County Hospital; Pulmonology Dept
Pécs, , Hungary
Sopron Megyei Jogu Varos Erzsebet Korhaza Mellkasgyogyaszat
Sopron, , Hungary
Tolna Megyei Balassa Janos Korhaz; Iv. Belgyogyaszati Osztaly
Szekszárd, , Hungary
Fejér Megyei Szent György Kórház; Pulmonary Medicine
Székesfehérvár, , Hungary
Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház; Onkológiai Osztály
Szolnok, , Hungary
Vas Megyei Markusovszky Korhaz ; Oncoradiology
Szombathely, , Hungary
Vas Megyei Markusovszky Korhaz ; Pulmonology
Szombathely, , Hungary
Komarom-Esztergom Megyei Onkormanyzat Szent Borbala Korhaz; Haematologiai Osztaly
Tatabánya, , Hungary
Inst. of Pulmonary Medicine, Torokbalint; 2Nd Dept of Pulmonary Medicine
Törökbálint, , Hungary
Zala Megyei Korhaz; Dept of Pulmonary Medicine
Zalaegerszeg, , Hungary
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tolnay E, Ghimessy AK, Juhasz E, Sztancsik Z, Losonczy G, Dombi P, Vennes Z, Helf L, Csada E, Sarosi V. The efficacy and safety of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer: Final results of AVALANCHE, an observational cohort study. Oncol Lett. 2019 Feb;17(2):1750-1760. doi: 10.3892/ol.2018.9766. Epub 2018 Nov 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML21783
Identifier Type: -
Identifier Source: org_study_id